Anacor Pharmaceuticals Announces Third Quarter 2013 Financial Results Conference Call and Webcast

  Anacor Pharmaceuticals Announces Third Quarter 2013 Financial Results
  Conference Call and Webcast

Business Wire

PALO ALTO, Calif. -- November 4, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for
the third quarter ended September 30, 2013, on Thursday, November 7, 2013 at
approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed
by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management
will discuss the company’s financial results and recent developments. The call
can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534
(international) five minutes prior to the start of the call. The call will
also be webcast live and can be accessed on the Events and Presentations page,
under Investors, on the company’s website at www.anacor.com and will be
available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, an antifungal for the treatment of
onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365, an antibiotic for the treatment of
infections caused by Gram-negative bacteria. Anacor has also discovered three
other compounds that have been out-licensed for further development — one is
licensed to Eli Lilly and Company for the treatment of an animal health
indication, the second compound, AN5568, also referred to as SCYX-7158, is
licensed to Drugs for Neglected Diseases initiative, or DNDi, for human
African trypanosomiasis (HAT, or sleeping sickness), and the third compound is
licensed to GlaxoSmithKline for development in tuberculosis. Anacor also has a
pipeline of other internally discovered topical and systemic boron-based
compounds in development. For more information, visit http://www.anacor.com.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com